Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005835 · ClinicalTrials.gov registry record · Phase 1
N99-02: Melphalan and Buthionine Sulfoximine
A Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 9
- Study locations
NCT00005835 is a Phase 1 study of Neuroblastoma that has completed, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 31 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT00005835, a Phase 1 study of Neuroblastoma, has completed, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children who have resistant or recurrent neuroblastoma.
Conditions Studied
Interventions
- DRUG melphalan
- DRUG buthionine sulfoximine
- PROCEDURE Peripheral blood stem cell infusion
- OTHER Filgrastim
Study Locations (9)
California
- Childrens Hospital Los Angeles - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Comer Children's Hospital - Chicago
Massachusetts
- Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Medical Center - Fort Worth - Fort Worth
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2001-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005835
The ClinicalTrials.gov registry entry for NCT00005835 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 4 interventions - of which melphalan is the first listed.
NCT00005835 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00005835 about?
NCT00005835 is a clinical study titled "N99-02: Melphalan and Buthionine Sulfoximine". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00005835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2001-08. Estimated completion is 2016-04.
What conditions does trial NCT00005835 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00005835?
The interventions under investigation include: melphalan (DRUG), buthionine sulfoximine (DRUG), Peripheral blood stem cell infusion (PROCEDURE), Filgrastim (OTHER).
Who is sponsoring clinical trial NCT00005835?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005835 being conducted?
This trial has 9 study locations across California, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.